The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Novel drug conjugates for multiple myeloma treatment
Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute, Charlotte, NC, discusses the latest updates in treatments for multiple myeloma. Dr Usmani discusses the CELMoDs iberdomide and mezigdomide (CC-92480), which have shown good molecular activity profiles as monotherapies and in combination with dexamethasone. Selinexor has also shown potential in myeloma, with the BOSTON trial (NCT03110562) of selinexor plus dexamethasone and bortezomib underway in heavily pre-treated patients. Recent data on the peptide-drug conjugate melflufen and the antibody-drug conjuate belantamab mafodotin is also promising. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx and Takeda; and has received speaking fees from Celgene, Janssen, Sanofi and Takeda.
